PBL
MCID: PLS025
MIFTS: 54

Plasmablastic Lymphoma (PBL)

Categories: Blood diseases, Immune diseases, Oral diseases, Rare diseases

Aliases & Classifications for Plasmablastic Lymphoma

MalaCards integrated aliases for Plasmablastic Lymphoma:

Name: Plasmablastic Lymphoma 54 60 74
Immunoblastic Large-Cell Lymphoma 74
Pbl 60

Classifications:



External Ids:

ICD10 via Orphanet 35 C83.3
UMLS via Orphanet 75 C3472614
Orphanet 60 ORPHA289666

Summaries for Plasmablastic Lymphoma

NIH Rare Diseases : 54 Plasmablastic lymphoma is an aggressive form of non-Hodgkin lymphoma. Although the condition most commonly occurs in the oral cavity, it can be diagnosed in many other parts of the body such as the gastrointestinal tract, lymph nodes, and skin. The exact underlying cause of plasmablastic lymphoma is poorly understood; however, it is often associated with suppression of the immune system (i.e. HIV infection, immunosuppressive therapy). There is currently no standard therapy for plasmablastic lymphoma. Treatment usually consists of chemotherapy with or without radiation therapy and hematopoietic stem cell transplantation.

MalaCards based summary : Plasmablastic Lymphoma, also known as immunoblastic large-cell lymphoma, is related to suppressor of tumorigenicity 3 and acquired immunodeficiency syndrome. An important gene associated with Plasmablastic Lymphoma is MYC (MYC Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Lenograstim and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and b cells, and related phenotypes are Reduced mammosphere formation and cellular

Wikipedia : 77 Plasmablastic lymphoma is a type of large B-cell lymphoma, recognized in the WHO 2008... more...

Related Diseases for Plasmablastic Lymphoma

Diseases related to Plasmablastic Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 156)
# Related Disease Score Top Affiliating Genes
1 suppressor of tumorigenicity 3 30.5 CDKN2A MYC
2 acquired immunodeficiency syndrome 30.5 BCL6 CD38 MYC
3 plasmacytoma 30.5 CD38 MYC PTPRC
4 lymphocytic leukemia 30.5 CD38 MYC NOTCH1
5 primary effusion lymphoma 30.3 BCL6 MYC
6 diffuse large b-cell lymphoma 30.2 BCL6 MYC PRDM1
7 richter's syndrome 30.0 CD38 MYC NOTCH1
8 small cell cancer of the lung 30.0 ABCB1 CDKN2A MYC
9 burkitt lymphoma 29.6 BCL6 MS4A1 MYC
10 leukemia, chronic lymphocytic 29.6 ABCB1 BCL6 CD38 MS4A1 NOTCH1
11 mantle cell lymphoma 29.4 BCL6 CDKN2A MTOR MYC PTPRC
12 b-cell lymphomas 29.4 BCL6 CDKN2A MS4A1 MYC PRDM1
13 caspase 8 deficiency 11.2
14 lymphoma 11.1
15 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.4 BCL6 MYC
16 primary mediastinal large b-cell lymphoma 10.4 BCL6 MYC
17 heart lymphoma 10.4 BCL6 PTPRC
18 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.4 BCL6 PTPRC
19 testicular lymphoma 10.4 BCL6 PTPRC
20 primary cutaneous anaplastic large cell lymphoma 10.4 MUC1 PTPRC
21 ovarian lymphoma 10.4 MYC PTPRC
22 malignant peritoneal mesothelioma 10.3 CDKN2A MUC1
23 peritoneal mesothelioma 10.3 CDKN2A MUC1
24 epidural neoplasm 10.3 BCL6 PTPRC
25 cutaneous leiomyosarcoma 10.3 DES MUC1
26 spindle cell thymoma 10.3 DES MUC1
27 endometrial mucinous adenocarcinoma 10.3 CDKN2A MUC1
28 bile duct adenoma 10.3 CDKN2A MUC1
29 parachordoma 10.3 DES MUC1
30 primitive neuroectodermal tumor of the cervix uteri 10.3 DES PTPRC
31 syringocystadenoma papilliferum 10.3 DES MUC1
32 megaesophagus 10.3 CDKN2A MYC
33 gamma heavy chain disease 10.3 CD38 PTPRC
34 ossifying fibromyxoid tumor 10.3 DES MUC1
35 malignant fibrous histiocytoma of bone 10.3 DES MYC
36 spindle cell rhabdomyosarcoma 10.3 DES MUC1
37 sarcomatoid mesothelioma 10.3 CDKN2A MUC1
38 biphasic synovial sarcoma 10.3 DES MUC1
39 syringoma 10.3 DES MUC1
40 multicentric castleman disease 10.3 ABCB1 BCL6
41 mucinous bronchioloalveolar adenocarcinoma 10.3 CDKN2A MUC1
42 desmoplastic small round cell tumor 10.3 DES MUC1
43 hepatic angiomyolipoma 10.3 MTOR MYC
44 human herpesvirus 8 10.3
45 crohn's disease 10.3
46 lymphatic system cancer 10.3 BCL6 MYC PTPRC
47 perivascular epithelioid cell tumor 10.3 DES MUC1
48 well-differentiated liposarcoma 10.2 CDKN2A MUC1
49 proximal spinal muscular atrophy 10.2 DES MUC1
50 reticulosarcoma 10.2 BCL6 MUC1 PTPRC

Graphical network of the top 20 diseases related to Plasmablastic Lymphoma:



Diseases related to Plasmablastic Lymphoma

Symptoms & Phenotypes for Plasmablastic Lymphoma

GenomeRNAi Phenotypes related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 BCL6 DES MTOR MYC NOTCH1 PTPRC

MGI Mouse Phenotypes related to Plasmablastic Lymphoma:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.21 BCL6 CD38 CDKN2A DES MTOR MYC
2 cardiovascular system MP:0005385 10.18 ABCB1 BCL6 CDKN2A DES MTOR MYC
3 endocrine/exocrine gland MP:0005379 10.18 ABCB1 BCL6 CD38 CDKN2A MTOR MYC
4 hematopoietic system MP:0005397 10.17 ABCB1 BCL6 CD38 CDKN2A MS4A1 MTOR
5 homeostasis/metabolism MP:0005376 10.14 ABCB1 BCL6 CD38 CDKN2A DES MTOR
6 growth/size/body region MP:0005378 10.11 ABCB1 BCL6 CDKN2A MTOR MYC NOTCH1
7 immune system MP:0005387 10.11 ABCB1 BCL6 CD38 CDKN2A MS4A1 MTOR
8 digestive/alimentary MP:0005381 9.97 ABCB1 CDKN2A MYC NOTCH1 PTPRC VDR
9 mortality/aging MP:0010768 9.96 ABCB1 BCL6 CDKN2A DES MTOR MYC
10 liver/biliary system MP:0005370 9.87 ABCB1 BCL6 CDKN2A MYC NOTCH1 PRDM1
11 muscle MP:0005369 9.76 BCL6 CDKN2A DES MTOR MYC NOTCH1
12 neoplasm MP:0002006 9.35 CDKN2A MYC NOTCH1 PRDM1 PTPRC
13 no phenotypic analysis MP:0003012 9.17 ABCB1 BCL6 CDKN2A MTOR MYC PRDM1

Drugs & Therapeutics for Plasmablastic Lymphoma

Drugs for Plasmablastic Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 458)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
3
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-24-4 5453
4 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
5 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
7 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
8 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
11
Clavulanate Approved, Vet_approved Phase 3,Not Applicable 58001-44-8 5280980
12 Orange Approved Phase 3
13
Amoxicillin Approved, Vet_approved Phase 3,Not Applicable 26787-78-0 33613
14
Ciprofloxacin Approved, Investigational Phase 3,Not Applicable 85721-33-1 2764
15
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
16
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
17
Ofloxacin Approved Phase 3 82419-36-1 4583
18
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 460612 4053
19
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
20
Idarubicin Approved Phase 3 58957-92-9 42890
21
Etoposide Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
22
Cytarabine Approved, Experimental, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4, 65-46-3 6253
23
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
24
Bleomycin Approved, Investigational Phase 3,Phase 1,Phase 2 11056-06-7 5360373
25
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
26
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
27
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154-93-8 2578
28
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
29
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
30
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
31
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
32
Mitoxantrone Approved, Investigational Phase 3,Phase 1,Phase 2 65271-80-9 4212
33
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
34
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
35
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
36
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
37
rituximab Approved Phase 3,Phase 1,Phase 2,Not Applicable 174722-31-7 10201696
38
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
39
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
40
Carboplatin Approved Phase 2, Phase 3,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
41
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
42
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
43
Mesna Approved, Investigational Phase 3,Phase 1,Phase 2 3375-50-6 598
44
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
45
Aldesleukin Approved Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4
46
Tazobactam Approved Phase 3 89786-04-9 123630
47
Vancomycin Approved Phase 3 1404-90-6 441141 14969
48
Piperacillin Approved Phase 3 66258-76-2 43672
49
Iron Approved, Experimental Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6, 15438-31-0 23925 27284
50
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2

Interventional clinical trials:

(show top 50) (show all 544)
# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
3 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
4 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
5 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
6 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
7 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
8 Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00003815 Phase 3 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisolone;vincristine sulfate
9 Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
10 High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003578 Phase 3 CHOP regimen;carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisone;vincristine sulfate
11 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
12 Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma Completed NCT00002565 Phase 3 CHOP regimen;cisplatin;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;idarubicin;ifosfamide;mesna;methylprednisolone;mitoxantrone hydrochloride;prednisone;vincristine sulfate
13 Combination Chemotherapy in Treating Patients With Lymphoma Completed NCT00002835 Phase 3 Carmustine;Cisplatin (CDDP);Cyclophosphamide;Cytarabine (ARA-C);Etoposide (VP-16);Idarubicin;Ifosfamide;Leucovorin Calcium;Melphalan;Methotrexate;Methylprednisolone;mitoxantrone hydrochloride (DHAD);Vincristine Sulfate
14 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
15 Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
16 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
17 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
18 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma Completed NCT00003595 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
19 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
20 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
21 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
22 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
23 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
24 Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma Completed NCT00002576 Phase 3 cyclophosphamide;doxorubicin hydrochloride;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
25 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
26 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
27 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
28 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
29 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
30 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma Completed NCT00003150 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
31 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma Completed NCT00003215 Phase 3 CHOP regimen;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;leucovorin calcium;melphalan;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;therapeutic hydrocortisone;vincristine sulfate
32 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
33 Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Completed NCT00005867 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
34 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
35 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
36 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
37 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
38 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
39 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
40 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
41 SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00004031 Phase 3 CHOP regimen;carmustine;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
42 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
43 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
44 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
45 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
46 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
47 Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma Completed NCT00002618 Phase 3 cytarabine;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;vincristine sulfate
48 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
49 Rituxan vs Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (BMT CTN 0401) Completed NCT00329030 Phase 3 Autologous transplantation using rituxan/BEAM;Autologous transplantation using Bexxar/BEAM
50 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3 glutamic acid

Search NIH Clinical Center for Plasmablastic Lymphoma

Genetic Tests for Plasmablastic Lymphoma

Anatomical Context for Plasmablastic Lymphoma

MalaCards organs/tissues related to Plasmablastic Lymphoma:

42
Bone, Bone Marrow, B Cells, T Cells, Liver, Kidney, Lymph Node

Publications for Plasmablastic Lymphoma

Articles related to Plasmablastic Lymphoma:

(show top 50) (show all 332)
# Title Authors Year
1
Follicular lymphoma suggested to transform into EBV-negative plasmablastic lymphoma. ( 30859398 )
2019
2
Plasmablastic lymphoma presenting with ileocecal intussusception in an immunocompetent patient. ( 30808128 )
2019
3
A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma. ( 30906602 )
2019
4
Primary central nervous system plasmablastic lymphoma in an HIV-positive patient. ( 30872336 )
2019
5
Clinicopathologic Features, Management and Outcomes of Plasmablastic Lymphoma: A Ten-Year Experience. ( 30734351 )
2019
6
Plasmablastic lymphoma of the rectum, a rare cause of lower gastrointestinal bleeding: A case report. ( 30665721 )
2019
7
Plasmablastic lymphoma of bone marrow: Report of a rare case and immunohistochemistry based approach to the diagnosis. ( 30706870 )
2019
8
Plasmablastic lymphoma presenting as a ureteral polypoid mass. ( 29692511 )
2018
9
Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma. ( 29679112 )
2018
10
Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis. ( 29303024 )
2018
11
SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target. ( 29785767 )
2018
12
Dual Threat of Epstein-Barr Virus: an Autopsy Case Report of HIV-Positive Plasmablastic Lymphoma Complicating EBV-Associated Hemophagocytic Lymphohistiocytosis. ( 29687211 )
2018
13
Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma. ( 29753690 )
2018
14
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report. ( 29879938 )
2018
15
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. ( 29527667 )
2018
16
First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature. ( 29456531 )
2018
17
Clinicopathological analysis of oral plasmablastic lymphoma: A systematic review. ( 29917262 )
2018
18
Orbital plasmablastic lymphoma. ( 29375870 )
2018
19
Transformation of double-hit follicular lymphoma to plasmablastic lymphoma: a partial role of MYC gene rearrangement. ( 30012920 )
2018
20
Plasmablastic Lymphoma in an Immunocompetent Patient with MDS/MPN with Ring Sideroblasts and Thrombocytosis-A Case Report. ( 30524760 )
2018
21
Radiological-Pathological Correlation in Plasmablastic Lymphoma in an Immunocompromised Patient. ( 30420931 )
2018
22
Plasmablastic lymphoma masquerading solitary plasmacytoma in an immunocompetent patient. ( 30344143 )
2018
23
An enlarging pacemaker pocket: A case report of a plasmablastic lymphoma arising as a primary tumor around a cardiac pacemaker and systematic literature review of various malignancies arising at the pacemaker pocket. ( 30279851 )
2018
24
EBV infection determines the immune hallmarks of plasmablastic lymphoma. ( 30288350 )
2018
25
Central nervous system plasmablastic lymphoma evolving from polyclonal plasmacytosis. ( 29984820 )
2018
26
Plasmablastic lymphoma in Malawi. ( 29988350 )
2018
27
Plasmablastic lymphoma: Review of 60 Chinese cases and prognosis analysis. ( 28248855 )
2017
28
Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review. ( 29387498 )
2017
29
Plasmablastic Lymphoma. ( 28746329 )
2017
30
Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma. ( 28249941 )
2017
31
Plasmablastic Lymphoma in a Patient With Crohn's Disease After Extensive Immunosuppressive Therapy. ( 28782668 )
2017
32
Bortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat disease. ( 28963907 )
2017
33
Oral plasmablastic lymphoma as the first manifestation of AIDS. ( 29267464 )
2017
34
Durable remission is achievable with localized treatment and reduction of immunosuppression in limited stage EBV-related plasmablastic lymphoma. ( 28831541 )
2017
35
A case of HIV-negative plasmablastic lymphoma of the bone marrow with a unique immunophenotype. ( 28588836 )
2017
36
Long-Term Survival of Primary Intracranial Plasmablastic Lymphoma: Case Report and Review of the Literature. ( 27794513 )
2017
37
Interleukin-6-dependent growth in a newly established plasmablastic lymphoma cell line and its therapeutic targets. ( 28860565 )
2017
38
Intraocular Plasmablastic Lymphoma in a HIV Patient. ( 28929004 )
2017
39
Unusual presentation of plasmablastic lymphoma involving ovarian mature cystic teratoma: a case report. ( 29187222 )
2017
40
Plasmablastic lymphoma with unfavorable chromosomal abnormalities related to plasma cell myeloma: A borderline case between plasmablastic lymphoma and plasmablastic plasma cell myeloma ( 28679965 )
2017
41
Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma. ( 28993364 )
2017
42
MicroRNAs sequencing unveils distinct molecular subgroups of plasmablastic lymphoma. ( 29296171 )
2017
43
Primary cutaneous plasmablastic lymphoma presenting as perineal ulcero-proliferative growth in a human immunodeficiency virus-seropositive patient. ( 27779143 )
2017
44
Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course? ( 29081245 )
2017
45
Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1. ( 27687004 )
2017
46
Plasmablastic lymphoma presenting as exophytic skin lesions. ( 28700895 )
2017
47
Plasmablastic Lymphoma: Case Report of Prolonged Survival of an Advanced Human Immunodeficiency Patient and Literature Review. ( 29090101 )
2017
48
Mediastinal syndrome from plasmablastic lymphoma in human immunodeficiency virus and human herpes virus 8 negative patient with polycythemia vera: a case report. ( 28320457 )
2017
49
Pediatric plasmablastic lymphoma: Diagnostic and therapeutic dilemma. ( 28631667 )
2017
50
A Case of Plasmablastic Lymphoma Achieving Complete Response and Durable Remission after Lenalidomide-Based Therapy. ( 28095384 )
2017

Variations for Plasmablastic Lymphoma

Expression for Plasmablastic Lymphoma

Search GEO for disease gene expression data for Plasmablastic Lymphoma.

Pathways for Plasmablastic Lymphoma

Pathways related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1 12.62 CDKN2A MTOR MYC NOTCH1
2
Show member pathways
12.32 ABCB1 CDKN2A MTOR MYC NOTCH1
3
Show member pathways
12.27 BCL6 MTOR MYC NOTCH1
4 12.22 BCL6 CD38 PRDM1 PTPRC
5 11.96 CDKN2A MTOR MYC
6 11.85 BCL6 PRDM1 VDR
7 11.83 ABCB1 CDKN2A MTOR MYC NOTCH1
8 11.75 MTOR MYC NOTCH1
9 11.73 BCL6 CDKN2A MYC
10 11.71 BCL6 MUC1 MYC
11 11.68 CDKN2A MTOR MYC
12 11.52 CD38 MS4A1 NOTCH1 PTPRC
13 11.41 CD38 MS4A1 PTPRC
14
Show member pathways
11.36 CDKN2A MTOR PRDM1
15 10.92 CDKN2A MYC
16
Show member pathways
10.91 CDKN2A MYC
17 10.78 ABCB1 VDR
18 10.75 BCL6 CD38 MS4A1 PRDM1 PTPRC
19 10.71 ABCB1 VDR
20 10.7 ABCB1 MTOR

GO Terms for Plasmablastic Lymphoma

Cellular components related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.36 BCL6 CD38 CDKN2A DES MS4A1 MTOR

Biological processes related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.83 BCL6 MYC NOTCH1 PRDM1 VDR
2 negative regulation of cell proliferation GO:0008285 9.78 BCL6 CDKN2A NOTCH1 VDR
3 regulation of cell proliferation GO:0042127 9.69 BCL6 NOTCH1 PRDM1
4 negative regulation of transcription, DNA-templated GO:0045892 9.65 BCL6 CD38 CDKN2A NOTCH1 VDR
5 response to gamma radiation GO:0010332 9.52 MYC PTPRC
6 negative regulation of cell-matrix adhesion GO:0001953 9.49 BCL6 CDKN2A
7 energy reserve metabolic process GO:0006112 9.4 MTOR MYC
8 positive regulation of keratinocyte differentiation GO:0045618 9.37 NOTCH1 VDR
9 positive regulation of B cell proliferation GO:0030890 9.33 BCL6 CD38 PTPRC
10 somatic stem cell division GO:0048103 9.32 CDKN2A NOTCH1
11 cell cycle arrest GO:0007050 9.26 CDKN2A MTOR MYC NOTCH1
12 positive regulation of glial cell proliferation GO:0060252 9.16 MTOR
13 positive regulation of gene expression GO:0010628 9.1 CDKN2A MTOR MYC NOTCH1 PRDM1 VDR

Molecular functions related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.62 MUC1 MYC NOTCH1 PRDM1
2 DNA-binding transcription factor activity GO:0003700 9.55 BCL6 MYC NOTCH1 PRDM1 VDR
3 sequence-specific DNA binding GO:0043565 9.26 BCL6 NOTCH1 PRDM1 VDR
4 chromatin DNA binding GO:0031490 8.8 BCL6 NOTCH1 PRDM1
5 protein binding GO:0005515 10.03 ABCB1 BCL6 CDKN2A DES MS4A1 MTOR

Sources for Plasmablastic Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....